Forward-Looking Statements Disclaimer This presentation has been prepared by Cue Biopharma, Inc. ("we," "us," "our," "Cue" or the "Company") and is made for informational purposes only and does not constitute an offer to

Corporate Presentation Immune

Responses, On Cue Nasdaq: CUE Oppenheimer 31st Annual Healthcare Conference, March 18, 2021 Exhibit 99.1

Forward-Looking Statements Disclaimer

This presentation has been prepared by Cue Biopharma, Inc. ("we," "us," "our," "Cue" or the "Company") and is made for informational purposes only and does not constitute an offer to sell

or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws

of any such state or jurisdiction. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated

otherwise, and neither this presentation, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised

to reflect information that subsequently becomes available or changes occurring after the date hereof. This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended,

and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our

future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would,"

"could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future, "vision",

"likely" or other comparable terms. All statements other than statements of historical facts included in this presentation regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are

forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding our development plans for CUE-101 and the continued buildout of our pipeline, the sufficiency of our cash, cash equivalents and

marketable securities to support the clinical development of CUE-101, anticipated results of our drug development efforts, including study results, our expectations regarding the timing of milestone events, regulatory developments and expected

future operating results. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future

plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that

are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these

forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, our limited operating history, limited cash

and a history of losses; our ability to achieve profitability; potential setbacks in our research and development efforts including negative or inconclusive results from our preclinical studies, our ability to secure required U.S. Food and Drug

Administration ("FDA") or other governmental approvals for our product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including COVID-19, including possible effects on our

operations and clinical trials; negative or inconclusive results from our clinical studies or serious and unexpected drug-related side effects or other safety issues experienced by participants in our clinical trials; delays and changes in

regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; our reliance on licensors, collaborators, contract research organizations, suppliers and other business partners;

our ability to obtain adequate financing to fund our business operations in the future; our ability to maintain and enforce necessary patent and other intellectual property protection, competitive factors, general economic and market conditions; and

the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and any subsequently filed

Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by us in this presentation is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update

any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Rationally Engineered Biologics to

Harness Nature's Cues for Selective and Specific Immune Modulation

Restoring Immune Balance

The Immuno-STAT platform has the

potential to generate a diversity of therapeutic molecules to selectively target and modulate the activity of a broad range of disease-relevant T cells Immuno-STAT: Emulating Nature's Cues to Selectively Modulate T Cells Source: Dustin, Cancer

Immunol Res 2014 Immuno-STAT Framework Single molecule Stable, off-the-shelf IV or SQ administration No ex vivo manipulation Peptide Antigen Peptide epitopes to target different diseases MHC Different HLA alleles to address global patient

populations Co-Stim/Co-Reg Distinct biological signals, including cytokines; cell-surface receptors; and/or other targeting modalities (e.g., scFv, etc.) Fc Backbone Fc engineering to dial in or out biological and effector functions Platform

Modularity Co-Stimulatory/ Co-Regulatory Receptor MHC presenting antigen Antigen- specific TCR Co-Stimulatory/ Co-Regulatory Signal Signal 2 Induction/ Control Signal 1 Selectivity/ Specificity Antigen-Presenting Cell (APC) T Cell Immune Synapse TCR

= T Cell Receptor MHC = Major Histocompatibility Complex

CUE-101: Designed to Selectively Prime

and Expand HPV-Specific T Cells CUE-101 Immuno-STAT Design Signal 1: HLA-A*02:01 + HPV-16 E711-20 peptide Signal 2: Modified IL-2 (IL-2 variant) Clinical Rationale HPV is recognized as a growing driver of head and neck cancer in the US; despite

treatment with current standards of care, >50% of patients with advanced disease will experience recurrence The HPV-16 E7 protein is a primary driver of tumorigenesis and the E7 peptide presented by CUE-101 is a highly conserved T cell epitope

and is immunogenic The CUE-101 clinical development strategy builds upon robust translational preclinical data1 and patient stratification2 Fc 1: Quayle et al., Clin Cancer Res Jan 2020 DOI: 10.1158/1078-0432.CCR-19-3354 2: Patients must be

HLA:02:01 and HPV-16+

CUE-101: Phase 1 Clinical Development

Network Emory Winship Cancer Institute | Nabil Saba Karmanos Cancer Institute | Elizabeth Heath and Ammar Sukari MD Anderson Cancer Center | Bonnie Glisson Memorial Sloan Kettering Cancer Center | Lara Dunn MGH/Harvard and Dana Farber Cancer

Institute | Sara Pai and Lori Wirth Moffitt Cancer Center | Christine Chung Sidney Kimmel Comprehensive Cancer Center-Johns Hopkins | Tanguy Seiwert Stanford Cancer Center | A. Dimitrios Colevas University of Arizona Center | Julie Bauman University

of Michigan Rogel Cancer Center | Frank Worden University of Washington Fred Hutch Cancer Center | Cristina Rodriguez Vanderbilt-Ingram Cancer Center | Jill Gilbert and Mike Gibson Washington University Siteman Cancer Center | Doug Adkins Yale

Cancer Center | Barbara Burtness Cue Biopharma has engaged a network of nationally recognized clinical investigators and 14 Phase 1 sites are now open

CUE-101: Ongoing Monotherapy

First-In-Human Phase 1 Trial Part A: Monotherapy Dose Escalation (Q3W, 3 + 3 design, with expansion up to 9 patients per cohort) Part B: Monotherapy Expansion (up to 20 total patients) CUE-101 Dose (mg/kg) 8.0 4.0 Dose (mg/kg) 2.0 1.0 0.54 0.18 0.06

Abbreviations: CPI, checkpoint inhibitors; HPV, human papilloma virus; PK/PD, pharmacokinetics/pharmacodynamics; Q3W, once every 3 weeks; rhIL-2, recombinant human interleukin-2; RECIST, Response Evaluation Criteria for Solid Tumors; RP2D,

Recommended Phase 2 Dose Cohort 1 Cohort 7 Cohort 5 Cohort 4 Cohort 3 Cohort 2 Cohort 6 Dosing complete Expansion up to 9 pts per cohort ongoing Molar IL-2 content equivalent to approved rhIL-2 (aldesleukin) dose Indication: HPV+ Recurrent or

metastatic head and neck cancer with confirmed progressive disease Heavily pretreated: Refractory or resistant to 1st line platinum-based chemotherapy and/or CPIs Parts A & B: Primary endpoints: Safety and tolerability Secondary endpoints: PK/PD

Anti-tumor activity per RECIST 1.1 ClinicalTrials.gov: NCT03978689 CUE-101 has been well tolerated through 7 cohorts with evidence of clinical activity Currently expanding Cohort 4, 5, and 6

CUE-101: Cohort 4 Case Study -

3rd line Systemic Treatment Treatment Timeline Outcome 1 Robotic transoral resection tongue base First intervention Curative intent 2 Adjuvant RT 1 mo Curative intent 3 Carboplatin + fluorouracil + cetuximab for advanced, metastatic disease 1 yr, 1

mo Duration: 6.0 weeks Best Response = SD 4 RT to metastatic mass 1 yr, 4 mos Palliation 5 Pembrolizumab for advanced, metastatic disease 2 yrs Duration: 9.4 weeks Best Response = PD 6 CUE-101 (1 mg/kg, Q3W) 2 yrs, 5 mos Duration: 18.1 weeks ECOG

Status: 0 at screening; Unchanged while on CUE-101 therapy All TRAEs Grade 2 Tolerability CUE-101 Best Response: Confirmed SD by RECIST 1.1 for 18 weeks

CUE-101: Cohort 4 Case Study -

PK, PD, Response CUE-101 Best Response: Confirmed SD by RECIST 1.1 for 18 weeks >7-fold increase Pre-Dose Week 15 (C1D1) (C5D1) One target lesion at baseline: Diameter: 58 mm No change for 20 wks PD SD SD PR Pharmacodynamics: Increase in

peripheral blood E7-specific T cells 0 24 48 72 96 120 144 168 Hours Post Start of Infusion [CUE-101] (ng/mL) 104 103 102 101 Cohort 1 Cohort 2 Cohort 3 Cohort 4 Pharmacokinetics: Dose proportional

CUE-101: Cohort 4 Case Study -

Necrosis and a T Cell Infiltrate Hematoxylin and eosin stain (cell nuclei = blue; extracellular matrix and cytoplasm = pink) Cohort 4 (1 mg/kg) patient was on therapy for over 18 weeks Immunostaining (cell nuclei = blue; CD8+ T cells = rose; PD-LI =

CUE-101: Cohort 5 Case Study -

PK, Response PD SD Tumor Node 2 Node 1 SOD Pharmacokinetics: Dose proportional CUE-101 Best Response: Confirmed SD by RECIST 1.1 for 28 weeks; acquired COVID-19 and came off study 0 48 96 144 192 240 288 336 Hours Post Start of Infusion 105 104 103

102 101 [CUE-101] (ng/mL) Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 Three target lesions at baseline: Tumor mass: 11 mm Lymph node No.1: 15 mm Lymph node No. 2: 24 mm Sum of Diameters (SOD) = 50 mm

Dose-dependent, sustained increase

in NKs with transient increase in Tregs, consistent with IL-2 pharmacology observed in the clinic CUE-101: Induced Changes in NK Cells and Tregs in Cohorts 1 - 7 NK cells Tregs Cohorts 1 and 2 Cohort 3 Cohort 4 Cohort 5 Cohort 6 Cohort 7

CUE-101: Ongoing Pembrolizumab

Combination Study Part C: Pembrolizumab Combination Dose Escalation Part D: Combination Expansion at RP2D Dose Pembrolizumab 200 mg, Q3W CUE-101 Dose (mg/kg) 4.0 Dose (mg/kg) 2.0 1.0 Abbreviations: PD, pharmacodynamics; PK, pharmacokinetics; RP2D,

Recommended Phase 2 Dose ClinicalTrials.gov: NCT03978689 Eligibility: HPV+ Head and neck cancer Recurrent or metastatic (R/M) 1st Line HLA-A*0201 genotype Life expectancy 12 weeks Eligible for pembrolizumab in the first-line setting Design:

Dosing Q3W Part C: 3 + 3 Dose escalation with 1-week safety follow up of 1st patient required at each dose prior to dosing patients 2 and 3 Part C: PD and activity expansion up to 9 patients Part D: Expansion to total of 10-20 patients at RP2D

Objectives: Primary: Safety and tolerability Secondary: PK/PD, Anti-tumor activity Biomarkers: (Pre/Post CUE-101 dose) HPV E7-specific CD8+ T cell counts and functionality Immunophenotyping, cytokine release, and TCR sequencing Same dose of CUE-101

as in Cohort 4 in the monotherapy trial Cohort 1 Cohort 3 Cohort 2 Initiated February 2021

CUE-101: Preclinical Studies Support

Pembrolizumab Combination Abbreviations: AgS, antigen-specific; mCUE-101, mouse surrogate of human CUE-101; PD1, anti-PD1 surrogate Tumor growth inhibition by mCUE-101 is greatly enhanced in combination with PD1 blockade PD1 +

mCUE-101 dosing period; 2 one-week cycles Expansion of functional HPV E7 antigen-specific CD8+ T cells in the tumor and periphery by mCUE-101 is greatly enhanced in combination with PD1 blockade Source: Quayle SN, Girgis N, et al. Clin Canc

Res 26:1953-64, 2020.

CUE-101, CUE-100 Series and

Derivatives Clinical development of the IL-2-based CUE-100 series (via CUE-101) demonstrates tolerability, dose proportional PK/PD and supports clinical efficacy KRAS G12V HPV CUE-101 IL-2 Variant Empty Neo-STATs Immuno-STATs Viral T cell epitope

Bi-specific RDI-STATs Tumor-targeting scFv Asia Rights: CUE-101 CUE-102 CUE-103 (TBD) IL-2-based CUE-100 Series Immuno- oncology Pipeline PROTEIN DESIGN TARGET SELECTION PRE-CLINICAL IND-ENABLING PHASE 1 (A)/(B) PHASE 2 CUE-102 WT1

CUE-100 Neo-STAT: Addresses Tumor

Heterogeneity Note empty MHC clefts Top View Neo-STAT scaffold manufactured in bulk Peptide antigen of interest CMV MART-1 Peptide mixes / Multi-antigen based cocktail therapy Integration of post-translationally modified peptides Difficult to

manufacture peptides / Altered peptide ligands Extension to cancer neoantigens Personalized medicine Potential Therapeutic Applications to include: 25 % of CMV-specific CD8+ T cells CMV CUE-100 Series IST CMV Neo-STAT MART-1 Neo-STAT % of

MART-1-specific CD8+ T cells MART-1 CUE-100 Series IST MART-1 Neo-STAT CMV Neo-STAT

RDI-STATs: Novel Bi-specifics

Re-directing Viral-Specific T Cells to Tumor Cells Viral T Cell Epitope (e.g., CMV) IL-2v HLA-A02 Tumor-Targeting TAA IgG Fc Bi-specific RDI-STAT CMV, cytomegalovirus; TAA, tumor-associated antigen; TIL, tumor-infiltrating lymphocyte Harnesses

a pre-existing and robust viral T cell repertoire present in high frequency Superior specificity: avoids systemic activation of ALL T cells Superior safety: minimizes cytokine release De-risked by CUE-101 clinical experience TAA Tumor cells

Anti-Viral T cell TIL KILLING

Approaches to Modulate Autoreactive

T Cell Responses Antigen-Specific Approach Pathway-Specific Approach AIM: Deploy class I/II Immuno-STATs to modulate autoreactive T cells and/or generate antigen-specific inhibitory Tregs AIM: Engineered key signals to restore immune balance through

generation of polyclonal induced Tregs (iTregs) Focus on diseases with restricted autoreactive antigens Focus on earlier stages of breakdown of tolerance prior to antigen/epitope spreading Focus on IL-2 and TGF- for iTreg induction and

expansion Focus on indications and chronic disease stages with diverse self-antigens CUE-300 Series CUE-400 Series Cue Biopharma is applying protein engineering and mechanistic biology to develop drug candidates applicable to both approaches T Cell

Mediated Autoimmune Diseases

Numbers: nTregs are limited

in numbers vs iTregs, which can be generated from the broader CD4+ T cell repertoire Diversity: TCR specificity of nTregs is pre-determined and fixed, while iTregs can be generated from vastly diverse polyclonal CD4+ T cells Phenotype: regulatory

phenotype of iTregs can be achieved and sustained via IL-2 and TGF-beta signals Disease impact: Conversion of pathogenic T cells into regulatory phenotype is an attractive therapeutic strategy for immune re-set Application: Broad applications for

iTregs in numerous autoimmune diseases, GVHD and transplantation CUE-401: Immune Balance Restoration via Induced Tregs (iTregs) IL-2 Variant (same as CUE-101) TGF-b Variant Fc Backbone CUE-401 Advantages for iTregs vs. nTregs

CUE-401: Induction of FoxP3+ iTregs

+ CUE-401 + recombinant cytokines Healthy donors 0.1 1 10 100 1000 10000 CUE-401 [nM] 0 20 40 60 80 i T r e g i n d u c t i o n [ % o f F o x p 3 + C D 4 + T c e l l s ] All assays performed in presence of TCR activation via CD3/CD28 stimulation

CUE-401 enhances iTregs as measured by induction of expression of the master Treg transcription factor FoxP3 + CUE-401 + recombinant cytokines IBD donors 0 20 40 60 80 i T r e g i n d u c t i o n [ % o f F o x p 3 + C D 4 + T c e l l s ] CUE-401

[nM] IBD donors + CUE-401 + recombinant cytokines RA donors 0 20 40 60 80 i T r e g i n d u c t i o n [ % o f F o x p 3 + C D 4 + T c e l l s ] CUE-401 [nM] RA donors

CUE-401: Suppression of T Cell